中文简介

《药物靶向》杂志发表了关于药物传递和分子和大分子药物靶向的所有方面的论文和评论，包括为这些药物的体外和/或体内应用设计和表征载体系统(胶体、蛋白质或聚合物)。论文不仅限于通过载体传递药物，还包括针对特定细胞或细胞外分子的分子和大分子药物的研究。因此，该杂志发表了包括基因/质粒DNA、基因沉默核酸(如小干扰RNA、反义寡核苷酸、核糖酶、DNAzymes)、适配体、单核苷酸和单克隆抗体及其偶联物在内的治疗肽/蛋白质和核酸的活性、传递和靶向性的研究结果。目标技术的诊断应用以及诊断和显像剂的靶向交付也属于该杂志的范围。此外，还寻求关于自我调节系统、对环境和外部刺激作出反应的系统以及能够产生程控、脉冲和其他复杂传递模式的系统的论文。药物杂志的目标也有论文的生理和其他生物障碍交付和定位,和手段,克服障碍,例如,通过渗透增强剂,并涵盖科目如溢出,在肿瘤扩散和目标组织,避免网状内皮系统,和小说交付系统的毒性测试和许可。

投稿网址：https://mc.manuscriptcentral.com/gdrt

英文简介

The Journal of Drug Targeting publishes papers and reviews on all aspects of drug delivery and targeting for molecular and macromolecular drugs including the design and characterization of carrier systems (whether colloidal, protein or polymeric) for both vitro and/or in vivo applications of these drugs. Papers are not restricted to drugs delivered by way of a carrier, but also include studies on molecular and macromolecular drugs that are designed to target specific cellular or extra-cellular molecules. As such the journal publishes results on the activity, delivery and targeting of therapeutic peptides/proteins and nucleic acids including genes/plasmid DNA, gene silencing nucleic acids (e.g. small interfering (si)RNA, antisense oligonucleotides, ribozymes, DNAzymes), as well as aptamers, mononucleotides and monoclonal antibodies and their conjugates. The diagnostic application of targeting technologies as well as targeted delivery of diagnostic and imaging agents also fall within the scope of the journal. In addition, papers are sought on self-regulating systems, systems responsive to their environment and to external stimuli and those that can produce programmed, pulsed and otherwise complex delivery patterns. The Journal of Drug Targeting also carries papers on the physiological and other biological barriers to delivery and targeting, and means of overcoming the barriers, for example, by penetration enhancers, and covers subjects such as extravasation, diffusion in tumours and target tissues, avoidance of the reticulo-endothelial system, and toxicity testing and licensing of novel delivery systems.